The insulin in dosage market size value per capita in Australia shows a steady decline from 2024 onwards. The forecasted values indicate a decrease from 21.08 USD in 2024 to 19.65 USD in 2028. Compared to the estimated value for 2023, there is a noticeable decrease year-on-year with a consistent decline observed in each subsequent year. The year-on-year variation from 2024 to 2025 is approximately -1.75%, from 2025 to 2026 is -1.74%, from 2026 to 2027 is -1.75%, and from 2027 to 2028 is -1.70%. This suggests an overall negative Compound Annual Growth Rate (CAGR) over this period.
Future trends to watch for include advancements in diabetes management technologies, potential changes in healthcare policies affecting insulin pricing, and the impacts of new insulin formulations entering the market. Additionally, demographic shifts and increased prevalence of diabetes might drive demand and could counterbalance some of the downward trends observed in the per capita market size value.
